BioSpace News Archive

uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-106 and future pipeline.

Myeloid Therapeutics, Inc. announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures.

Alltrna today announces the presentation of the first proof-of-concept data at multiple scientific forums this month.

Discovery Life Sciences ™ (Discovery), the Biospecimen and Biomarker Specialists ™, announced today that it has officially qualified as one of Akoya Biosciences’ global service providers.

ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide platform technology.

Poseida Therapeutics, Inc. today highlights its two oral and four poster presentations on the Company’s preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023.

RLS Inc. and Evergreen Theragnostics, Inc. announced a new agreement for RLS to prepare, sell and distribute doses of the drug candidate OCTEVY™ to PET customers across the US, if the product is approved by the Food and Drug Administration.

Orna Therapeutics presented data on the progress of lead program ORN-101, a development-stage in situ CAR program, at the Protein Engineering Summit (PEGS) and at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles.

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) today announced positive top line pilot study results for the StemSpine® procedure using AlloStem™ to treat chronic lower back pain.

SiteOne Therapeutics, Inc. today announced that it has received a grant (UG3DA058552) for up to $15 million from the National Institute on Drug Abuse (NIDA) for the development of STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.